![anti-PUMA, Polyclonal, Novus Biologicals 0.1mg; Unlabeled:Antibodies, Polyclonal | Fisher Scientific anti-PUMA, Polyclonal, Novus Biologicals 0.1mg; Unlabeled:Antibodies, Polyclonal | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/CCG/Novus-Biologicals/product-images/PUMA-Antibody-Immunohistochemistry-Paraffin-NBP1-76639-img0009.jpg-650.jpg)
anti-PUMA, Polyclonal, Novus Biologicals 0.1mg; Unlabeled:Antibodies, Polyclonal | Fisher Scientific
![CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire](https://mms.businesswire.com/media/20210225006284/en/861643/23/01_CANbridge_Logo_1.18_highres.jpg)
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
![Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/12/28/48523746-16091324892828562.jpg)
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
![PUMA facilitates EMI1-promoted cytoplasmic Rad51 ubiquitination and inhibits DNA repair in stem and progenitor cells | Signal Transduction and Targeted Therapy PUMA facilitates EMI1-promoted cytoplasmic Rad51 ubiquitination and inhibits DNA repair in stem and progenitor cells | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-021-00510-w/MediaObjects/41392_2021_510_Fig1_HTML.png)
PUMA facilitates EMI1-promoted cytoplasmic Rad51 ubiquitination and inhibits DNA repair in stem and progenitor cells | Signal Transduction and Targeted Therapy
![Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1554213706/Pumalounging.jpg/Pumalounging.jpg?VersionId=AXzRJpBb66kBzE1ipO.16_8WJAXmXjo2)